Journal of Personalized Medicine Review Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer Soukaina Boutriq 1,2,3, Alicia González-González 1,2 , Isaac Plaza-Andrades 1,2, Aurora Laborda-Illanes 1,2,3, Lidia Sánchez-Alcoholado 1,2,3, Jesús Peralta-Linero 1,2, María Emilia Domínguez-Recio 1, María José Bermejo-Pérez 1, Rocío Lavado-Valenzuela 2,*, Emilio Alba 1,4,* and María Isabel Queipo-Ortuño 1,2,4 1 Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA)-CIMES-UMA, 29010 Málaga, Spain;
[email protected] (S.B.);
[email protected] (A.G.-G.);
[email protected] (I.P.-A.);
[email protected] (A.L.-I.);
[email protected] (L.S.-A.);
[email protected] (J.P.-L.);
[email protected] (M.E.D.-R.);
[email protected] (M.J.B.-P.);
[email protected] (M.I.Q.-O.) 2 Instituto de Investigación Biomédica de Málaga (IBIMA), Campus de Teatinos s/n, 29071 Málaga, Spain 3 Facultad de Medicina, Universidad de Málaga, 29071 Málaga, Spain 4 Centro de Investigación Biomédica en Red de Cáncer (Ciberonc CB16/12/00481), 28029 Madrid, Spain * Correspondence:
[email protected] (R.L.-V.);
[email protected] (E.A.) Abstract: Endometrial cancer is one of the most common gynaecological malignancies worldwide. Histologically, two types of endometrial cancer with morphological and molecular differences and Citation: Boutriq, S.; also therapeutic implications have been identified. Type I endometrial cancer has an endometrioid González-González, A.; morphology and is estrogen-dependent, while Type II appears with non-endometrioid differentiation Plaza-Andrades, I.; Laborda-Illanes, and follows an estrogen-unrelated pathway.